Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

This week's publication of the New England Journal of Medicine evaluates the use of lanreotide in metastatic enteropancreatic neuroendocrine tumors.

News image

Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors.

However, data on their antitumor effects are limited.

Dr Martyn Caplin and colleagues conducted a randomized, double-blind, placebo-controlled, multinational study of the somatostatin analogue lanreotide in patients with advanced, well-differentiated or moderately differentiated, nonfunctioning, somatostatin receptor–positive neuroendocrine tumors of grade 1 or 2, and documented disease-progression status.

The tumors originated in the pancreas, midgut, or hindgut or were of unknown origin.

Patients were randomly assigned to receive an extended-release aqueous-gel formulation of lanreotide at a dose of 120 mg or placebo once every 28 days for 96 weeks.

The team's primary end point was progression-free survival, defined as the time to disease progression or death.

The estimated rate of progression-free survival at 24 months was 65% in the lanreotide group
New England Journal of Medicine

Secondary end points included overall survival, quality of life, and safety.

The research team observed that most patients had no tumor progression in the 3 to 6 months before randomization, and 33% had hepatic tumor volumes greater than 25%.

Lanreotide, as compared with placebo, was associated with significantly prolonged progression-free survival.

The team found that the estimated rates of progression-free survival at 24 months were 65% in the lanreotide group, and 33% in the placebo group.

The therapeutic effect in predefined subgroups was generally consistent with that in the overall population, with the exception of small subgroups in which confidence intervals were wide.

The researchers noted no significant between-group differences in quality of life or overall survival.

The most common treatment-related adverse event was diarrhea.

Dr Caplin's team concludes, "Lanreotide was associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic neuroendocrine tumors of grade 1 or 2."

N Engl J Med 2014; 371:224-233
18 July 2014

Go to top of page Email this page Email this page to a colleague

 25 April 2015

Advanced search
 24 April 2015 
GastroHep.com Easter break
 23 April 2015 
Gut microbiota modulation for alcoholic liver disease
 23 April 2015 
Moderate sodium restriction diet in cirrhosis
 23 April 2015 
Gastroesophageal junction disruption and obesity
 22 April 2015 
Hepatitis and mortality in hospitalized patients
 22 April 2015 
Magnetic sphincter augmentation for GERD
 22 April 2015 
Drug, herbal and dietary supplement hepatotoxicity
 21 April 2015 
Risk factors of postpartum bowel changes
 21 April 2015 
Tracking colonoscopy surveillance intervals
 21 April 2015 
PPI increases risk of cryptogenic liver abscess
 20 April 2015 
IBS after traveller's diarhea
 20 April 2015 
Economic impact of C. diff infection
 20 April 2015 
Adherence to Hep C treatments
 17 April 2015 
Synchronous colorectal advanced neoplasia
 17 April 2015 
PNPLA3 polymorphisms and NAFLD risk
 17 April 2015 
MELD score and colorectal resection
 16 April 2015 
Bleeding risk in colonic diverticulosis
 16 April 2015 
Minority use of high-volume hospitals for colorectal cancer
 16 April 2015 
Sleep and IBD
 15 April 2015 
Treatment of hepatocellular carcinoma
 15 April 2015 
Score predicts malignant bile duct obstruction
 15 April 2015 
Increased risk of Barrett esophagus
 14 April 2015 
Improving colorectal cancer screening uptake
 14 April 2015 
Colorectal cancer presenting under the age of 50
 14 April 2015 
Functional constipation vs constipation predominant IBS
 13 April 2015 
Fecal transplant for C. difficile
 13 April 2015 
Immune based treatments for HCC
 13 April 2015 
CRP and acute diverticulitis
 10 April 2015 
Hypnotherapy for IBS
 10 April 2015 
Adjuvant therapy after rectal cancer
 10 April 2015 
Viral outcomes in HCV infection
 09 April 2015 
Male IBD patients wishing to conceive
 09 April 2015 
Screening programs based on the fecal immunochemical test
 09 April 2015 
Management of esophageal food impaction
 08 April 2015 
Nonceliac gluten sensitivity
 08 April 2015 
Ambulatory hemorrhoidal surgery
 08 April 2015 
Iron fortification and gut inflammation
 07 April 2015 
Endoscopic managements of GI bleeds
 07 April 2015 
Interventions for eosinophilic esophagitis
 07 April 2015 
Treatment of Hep C virus
 06 April 2015 
Treatment for rectal cancer
 06 April 2015 
Risk stratifying Barrett's esophagus
 06 April 2015 
Cost-effectiveness of HCV
 03 April 2015 
Predicting advanced cancer in Barrett's
 03 April 2015 
Vitamin D deficiency and Hep B outcomes
 03 April 2015 
Hepatocellular carcinoma surveillance in cirrhosis
 02 April 2015 
Physical activity and NAFLD
 02 April 2015 
Genetic risk for Crohn's disease
 02 April 2015 
EUS for detection of pancreatic neuroendocrine tumors
 01 April 2015 
Analysis of liver fibrosis
 01 April 2015 
Obeticholic acid in primary biliary cirrhosis
 01 April 2015 
Mortality rates for upper GI bleeds
 31 March 2015 
HCV-HIV co-infection combination therapy
 31 March 2015 
Placement of nasoenteral feeding tubes
 31 March 2015 
Hepatic fat and gallbladder polyps
 30 March 2015 
Minimally invasive approach in colorectal procedures
 30 March 2015 
Prevalence of IBD in USA residents of Indian ancestry
 30 March 2015 
Treatment of pediatric IBD
 27 March 2015 
Screening for fecal incontinence
 27 March 2015 
Deep remission in Crohn's disease

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us